Document Detail

Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score.
MedLine Citation:
PMID:  15045145     Owner:  NLM     Status:  MEDLINE    
The overt DIC score of the DIC subcommittee of the ISTH includes a fibrin-related marker (FRM) as indicator of intravascular fibrin formation. The type of marker to be used has not been specified, but D-dimer antigen, or fibrin degradation products are used by most investigators. Soluble fibrin complexes have been suggested as more specific indicators of acute intravascular fibrin formation. The aim of the present study was to compare the predictive value of the overt DIC score concerning clinical outcome in a surgical intensive care cohort, using either D-dimer antigen, or soluble fibrin antigen as FRM. The cutoff values for 2 and 3 score points for the FRM were assigned on the basis of the 25% and 75% quartiles of 1870 plasma samples obtained from 359 ICU patients during a period of 6 months. For 331 patients with complete diagnostic workup and day 1 blood samples, the Iatro SF as FRM component of the overt DIC score displayed the highest prognostic power concerning clinical outcome. The 28-day mortality of patients with overt DIC at day 1, using Iatro SF as FRM assay was 50.0%, whereas 28-day mortality of patients without overt DIC was 14.0% (p <0.0001). Using MDA D-dimer, and TINAquant D-dimer, 28-day mortality was between 35.5% and 39.3% in patients with overt DIC, and 15.5% to 15.6% in patients without overt DIC. Selection of the FRM as component of the DIC score has a small, but relevant impact on the prognostic performance of the overt DIC score. The present data on the distribution of values may provide a basis for the selection of appropriate cutoff points for assigning 2, and 3 points in the score.
Carl-Erik Dempfle; Michael Wurst; Mathias Smolinski; Stephan Lorenz; Alexandra Osika; Daniela Olenik; Fritz Fiedler; Martin Borggrefe
Related Documents :
16988545 - A systematic review of antithrombin concentrate use in patients with disseminated intra...
8800625 - A risk-benefit assessment of ace inhibitor therapy post-myocardial infarction.
2424425 - The proteinase inhibitor complexes (antithrombin iii-thrombin, alpha 2antiplasmin-plasm...
16024335 - Effect of activated recombinant human factor 7 (niastase) on laboratory testing of inhi...
2787955 - Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia ...
12521835 - Findings in women with postmenopausal bleeding investigated with hysteroscopy.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Thrombosis and haemostasis     Volume:  91     ISSN:  0340-6245     ISO Abbreviation:  Thromb. Haemost.     Publication Date:  2004 Apr 
Date Detail:
Created Date:  2004-03-26     Completed Date:  2004-11-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7608063     Medline TA:  Thromb Haemost     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  812-8     Citation Subset:  IM    
University Hospital of Mannheim, I. Department of Medicine, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antigens / analysis
Biological Markers / analysis
Blood Coagulation Tests
Cohort Studies
Disseminated Intravascular Coagulation / diagnosis*,  mortality
Fibrin / analysis*,  immunology
Fibrin Fibrinogen Degradation Products / analysis*
Middle Aged
Practice Guidelines as Topic
Predictive Value of Tests
Prospective Studies
Societies, Medical
Reg. No./Substance:
0/Antigens; 0/Biological Markers; 0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D; 9001-31-4/Fibrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura fr...
Next Document:  Tibial slope changes following dome-type high tibial osteotomy.